TY - JOUR
T1 - Physiological concentrations of tissue factor pathway inhibitor do not inhibit prothrombinase
AU - Mast, Alan E.
AU - Broze, George J.
PY - 1996/3/1
Y1 - 1996/3/1
N2 - Tissue factor pathway inhibitor (TFPI) is a Kunitz-type serine proteinase inhibitor that directly inhibits factor Xa and, in a factor Xa dependent manner, inhibits the factor VIIa/tissue factor catalytic complex. The inhibitory effect of TFPI in prothrombin activation assays using purified components of the prothrombinase complex was examined. When factor Xa is added to mixtures containing TFPI, prothrombin, calcium ions, and nonactivated platelets or factor V and phospholipids, TFPI significantly reduces subsequent thrombin generation, and the inhibitory effect is enhanced by heparin. If factor Xa is preincubated with calcium ions and thrombin- activated platelets or factor Va and phospholipids to permit formation of prothrombinase before the addition of pro-thrombin and physiologic concentrations of TFPI (<8 nmol/L), minimal inhibition of thrombin generation occurs, even in the presence of heparin. Thus, contrary to results in amidolytic assays with chromogenic substrates, prothrombinase is resistant to inhibition by TFPI in the presence of its physiological substrate, prothrombin. Higher concentrations of TFPI (~100 nmol/L), similar to those used in animal studies testing for therapeutic actions of TFPI, do effectively block prothrombinase activity.
AB - Tissue factor pathway inhibitor (TFPI) is a Kunitz-type serine proteinase inhibitor that directly inhibits factor Xa and, in a factor Xa dependent manner, inhibits the factor VIIa/tissue factor catalytic complex. The inhibitory effect of TFPI in prothrombin activation assays using purified components of the prothrombinase complex was examined. When factor Xa is added to mixtures containing TFPI, prothrombin, calcium ions, and nonactivated platelets or factor V and phospholipids, TFPI significantly reduces subsequent thrombin generation, and the inhibitory effect is enhanced by heparin. If factor Xa is preincubated with calcium ions and thrombin- activated platelets or factor Va and phospholipids to permit formation of prothrombinase before the addition of pro-thrombin and physiologic concentrations of TFPI (<8 nmol/L), minimal inhibition of thrombin generation occurs, even in the presence of heparin. Thus, contrary to results in amidolytic assays with chromogenic substrates, prothrombinase is resistant to inhibition by TFPI in the presence of its physiological substrate, prothrombin. Higher concentrations of TFPI (~100 nmol/L), similar to those used in animal studies testing for therapeutic actions of TFPI, do effectively block prothrombinase activity.
UR - http://www.scopus.com/inward/record.url?scp=0030039385&partnerID=8YFLogxK
U2 - 10.1182/blood.v87.5.1845.bloodjournal8751845
DO - 10.1182/blood.v87.5.1845.bloodjournal8751845
M3 - Article
C2 - 8634431
AN - SCOPUS:0030039385
SN - 0006-4971
VL - 87
SP - 1845
EP - 1850
JO - Blood
JF - Blood
IS - 5
ER -